PeptideStack
5.2kquestions
20kanswers
220users

Would you accept 97.9% on tirzepatide from ERP without a content assay?

Asked 9 Aug 2024Modified 20 months agoViewed 37k times
34

Concretely: 97.9% · tirzepatide · ERP.

I want to decide this in advance so that I am not deciding it under pressure later.

Assume I will follow the plan I write down, so I would like it to be a good one.

What should I decide now, and what should I defer?

purity
purity

Purity as chromatographic area per cent - the fraction of detected material that is your target peak. It says nothing about how much material is…

833 questions
content-assay
content-assay

Quantified content: how many milligrams of peptide are actually in the vial, measured against a calibrated reference standard. A separate test…

476 questions
vendor-vetting
vendor-vetting

Evaluating a supplier on evidence rather than reputation: testing history across batches, whether certificates are batch-specific, how failures…

454 questions
tirzepatide
tirzepatide

A dual GIP and GLP-1 receptor agonist. Questions here cover the SURPASS and SURMOUNT programmes, the practical differences from a pure GLP-1…

370 questions
shareeditfollowflag
HL
askedharriet_lonsdale35k1389 Aug 2024

5 Answers

Sorted by votes
40

97.9 per cent purity with no content figure leaves the milligram number unmeasured. Purity says 97.9 of every 100 units of detected area is tirzepatide and 2.1 is something else. Content says how many milligrams are in the glass. The two do not constrain each other: a vial can be 97.9 per cent pure and still be under label, because water and counter-ion are part of the gross mass and neither shows up as an impurity peak. If you buy one test, buy the one that changes your arithmetic.

Understanding purity requires separating the chemistry from the method from the reporting convention, and the three are not independent.

Tailing factor measures peak shape, and a badly tailing peak spreads into the region where small impurities live, forcing tangent-skim integration that assigns tail area to the main peak.

Detection wavelength matters because 214 nm sees the peptide backbone while 280 nm sees only aromatic side chains — so truncation impurities lacking a tryptophan are invisible at 280 nm.

The ICH Q3A impurity thresholds and the relevant pharmacopoeial chapters all specify method validation requirements that almost no research-grade certificate claims to meet.

If you are ranking vendors, specify a method and have all samples tested at the same place.

shareimprove this answerflag
AB
answeredassay_blank45k3824 Oct 2024
2I would gently push back on the second point — inter-laboratory spread is wider than stated. – rhian_prydderch 2 months ago
3Worth adding that the method section is where the answer usually is. – Dr_Nadia_Farsi 4 months ago
add a comment
Sponsored

Sigma-Aldrich - Certified Reference Materials

Analytical standards and reagents with traceable certificates. Every quantitative result you read inherits the accuracy of the standard behind it.

Shop standards
25

Gradient slope is the most powerful parameter and almost nobody mentions it, which is why two reports on the same material disagree by a point.

Retention time is sequence-specific and method-specific, so comparing your result to a supplier value using a different method is meaningless without method documentation.

In practice, integration of the shoulder — whether you use perpendicular drop or tangent skim — determines what area gets assigned to the main peak versus the impurity table.

One qualification: achieving purity above roughly 98 per cent on a 30-residue peptide is fighting the chemistry of synthesis, not the quality of the purification.

The practical summary: ask for the chromatogram and the method, and ignore the headline number until you have both.

edited 15 Nov 2024 by nkem_obiora — corrected a unit error in the worked example

shareimprove this answerflag
NO
answerednkem_obiora39k384 Nov 2024
18

Identity and purity are orthogonal, and a high purity says almost nothing about whether the peak is actually what you think it is.

Buffer versus acid in the mobile phase changes the ionisation state of basic and acidic residues, shifting retention and selectivity — same vial, potentially different separation.

Mass on column affects detector linearity and peak overlap — overloading broadens peaks and hides neighbours, while underloading improves resolution but loses sensitivity.

Proline conformer interconversion kinetics are well-characterised and the half-life is of the same order as the chromatographic peak width at room temperature.

Compare purity within a single laboratory on the same method, never across laboratories.

shareimprove this answerflag
RC
answeredRP_C18105k3482 Oct 2024
3Do you have the chromatogram for this, or just the summary figure? – esther_vandeVelde 8 months ago
4Thank you — this is the answer I was looking for. – ines_brandt 2 hours ago
add a comment
16

Specifically, area percentage is not mass percentage, and conflating the two is the most common misreading of a purity figure.

Sample solvent strength affects peak shape — if you inject in strong solvent on a gradient starting in weak solvent, the solvent peak can distort your main peak or create a false shoulder.

Inter-laboratory studies on identical peptide material routinely find half-a-per-cent to a full-per-cent spreads in reported purity on the same sample.

If you only pay for one test, pay for quantified content. Purity is the number everyone quotes and content is the number that changes what you do.

shareimprove this answerflag
LD
answeredloss_on_drying40k13810 Sept 2024
14

Read the chromatogram before you read the number, because the number without the trace is not a measurement, it is a claim.

The fraction of your main peak that is actually your target versus isomers, fragments or related sequences is invisible without complementary identity testing.

I would be careful about over-reading a single measurement — treat it as a data point, not as ground truth.

In practice: ask for the chromatogram, check the method section, check the lot number against the vial, and set your accept threshold before you see the result rather than after.

shareimprove this answerflag
P9
answeredplate_count_9k78k24813 Oct 2024
4The impurity table is the part I now read first, and this explains why. – assay_blank 6 months ago
add a comment

Your answer

Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.

Not medical advice. Research-use-only compounds are not approved for human use.